STEREOSELECTIVITY OF (R)-HEXAHYDRO-DIFENIDOL AND (S)-HEXAHYDRO-DIFENIDOL BINDING TO NEUROBLASTOMA M1, CARDIAC M2, PANCREATIC M3, AND STRIATUM M4 MUSCARINIC RECEPTORS

被引:12
作者
WAELBROECK, M
CAMUS, J
TASTENOY, M
MUTSCHLER, E
STROHMANN, C
TACKE, R
LAMBRECHT, G
CHRISTOPHE, J
机构
[1] UNIV LIBRE BRUXELLES,SCH MED,DEPT BIOCHEM & NUTR,BLVD WATERLOO 115,B-1000 BRUSSELS,BELGIUM
[2] UNIV FRANKFURT,DEPT PHARMACOL,W-6000 FRANKFURT,GERMANY
[3] UNIV KARLSRUHE,INST INORGAN CHEM,W-7500 KARLSRUHE,GERMANY
关键词
HEXAHYDRO-DIFENIDOL ENANTIOMERS; MUSCARINIC RECEPTOR SUBTYPES M1; M2; M3; AND M4; STEREOSELECTIVE INTERACTION; DIFENIDOL; DICYCLIDOL;
D O I
10.1002/chir.530030207
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
(R)-Hexahydro-difenidol has a higher affinity for M1 receptors in NB-OK 1 cells, pancreas M3 and striatum M4 receptors (pK(i) 7.9 to 8.3) than for cardiac M2 receptors (pK(i) 7.0). (S)-Hexahydro-difenidol, by contrast, is nonselective (pK(i) 5.8 to 6.1). Our goal in the present study was to evaluate the importance of the hydrophobic phenyl, and cyclohexyl rings of hexahydro-difenidol for the stereoselectivity and receptor selectivity of hexahydro-difenidol binding to the four muscarinic receptors. Our results indicated that replacement of the phenyl ring of hexahydro-difenidol by a cyclohexyl group (--> dicyclidol) and of the cyclohexyl ring by a phenyl moiety (--> difenidol) induced a large (4- to 80-fold) decrease in binding affinity for all muscarinic receptors. Difenidol had a significant preference for M1, M3, and M4 over M2 receptors; dicyclidol, by contrast, had a greater affinity for M1 and M4 than for M2 and M3 receptors. The binding free energy decrease due to replacement of the phenyl and the cyclohexyl groups of (R)-hexahydro-difenidol by, respectively, a cyclohexyl and a phenyl moiety was almost additive in the case of M4 (striatum) binding sites. In the case of the cardiac M2, pancreatic M3, or NB-OK 1 M1 receptors the respective binding free energies were not completely additive. These results suggest that the four (R)-hexahydro-difenidol "binding moieties" (phenyl, cyclohexyl, hydroxy, and protonated amino group) cannot simultaneously form optimal interactions with the M1, M2, and M3 muscarinic receptors. When each of the hydrophobic groups is modified, the position of the whole molecule, relative to the four subsites, was changed to allow an optimal overall interaction with the muscarinic receptor.
引用
收藏
页码:118 / 123
页数:6
相关论文
共 23 条
[1]   COMPARISON OF AFFINITY CONSTANTS FOR MUSCARINE-SENSITIVE ACETYLCHOLINE RECEPTORS IN GUINEA-PIG ATRIAL PACEMAKER CELLS AT 29 DEGREESC AND IN ILEUM AT 29 DEGREESC AND 37 DEGREESC [J].
BARLOW, RB ;
BERRY, KJ ;
GLENTON, PAM ;
NIKOLAOU, NM ;
SOH, KS .
BRITISH JOURNAL OF PHARMACOLOGY, 1976, 58 (04) :613-620
[2]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[3]   STEREOSELECTIVE INHIBITION OF MUSCARINIC RECEPTOR SUBTYPES BY THE ENANTIOMERS OF HEXAHYDRO-DIFENIDOL AND ACETYLENIC ANALOGS [J].
FEIFEL, R ;
WAGNERRODER, M ;
STROHMANN, C ;
TACKE, R ;
WAELBROECK, M ;
CHRISTOPHE, J ;
MUTSCHLER, E ;
LAMBRECHT, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (03) :455-460
[4]   BINDING PROFILE OF A NOVEL CARDIOSELECTIVE MUSCARINE RECEPTOR ANTAGONIST, AF-DX 116, TO MEMBRANES OF PERIPHERAL-TISSUES AND BRAIN IN THE RAT [J].
HAMMER, R ;
GIRALDO, E ;
SCHIAVI, GB ;
MONFERINI, E ;
LADINSKY, H .
LIFE SCIENCES, 1986, 38 (18) :1653-1662
[5]   PIRENZEPINE DISTINGUISHES BETWEEN DIFFERENT SUBCLASSES OF MUSCARINIC RECEPTORS [J].
HAMMER, R ;
BERRIE, CP ;
BIRDSALL, NJM ;
BURGEN, ASV ;
HULME, EC .
NATURE, 1980, 283 (5742) :90-92
[6]   MUSCARINIC RECEPTOR SUBTYPES [J].
HULME, EC ;
BIRDSALL, NJM ;
BUCKLEY, NJ .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1990, 30 :633-673
[7]  
KORC M, 1987, J PHARMACOL EXP THER, V240, P118
[8]   AFFINITY PROFILES OF HEXAHYDRO-SILA-DIFENIDOL ANALOGS AT MUSCARINIC RECEPTOR SUBTYPES [J].
LAMBRECHT, G ;
FEIFEL, R ;
WAGNERRODER, M ;
STROHMANN, C ;
ZILCH, H ;
TACKE, R ;
WAELBROECK, M ;
CHRISTOPHE, J ;
BODDEKE, H ;
MUTSCHLER, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 168 (01) :71-80
[9]  
LEVINE RR, 1989, TRENDS PHARM S, V10
[10]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265